J&J's Ortho Biotech Inks 5-Year CRADA with NCI to Develop Cancer Immunotherapies | GenomeWeb

This article has been updated from a previous version to include comments from J&J and NCI officials about the agreement. The original version was published on June 5.

Ortho Biotech Oncology Research and Development and the National Cancer Institute will research and develop adoptive immunotherapies and genetically engineered T-cells as potential treatments for a variety of cancers, Ortho Biotech said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

DNA Sequencing is being used by researchers in California to survey fish and marine life as part of a conservation effort.

This week in Nature: Researchers describe the adaptation of organisms to environmental changes, while another study provides new insights into pig domestication.

The blog Sartorial Science seeks to challenge the stereotype of scientists as frumpy, messy, clueless dressers.

While one researcher says cloning the mammoth may be decades away, if successful, it may lead to a theme park of species that would no longer be extinct.